

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/682,303
Filing Date	October 9, 2003
First Named Inventor	Raul Trillo
Art Unit	1614
Examiner Name	
Attorney Docket Number	ANA-5955

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**


/Leonard Williams/ (05/09/2007)

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/682 303
--------------------	------------

Filing Date	October 9, 2003
-------------	-----------------

First Named Inventor	Trillo, Raul
----------------------	--------------

Art Unit	unknown
----------	---------

Examiner Name	unknown
---------------	---------

Attorney Docket Number	ANA-5955
------------------------	----------

Sheet	1	of	4
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁵
/LW/		WO 00/72820	12-07-2000	Abbot Laborat.		


/Leonard Williams/ (05/09/2007)

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/682,303

Filing Date October 9, 2000

First Named Inventor Trillo, Raul

Art Unit unknown

Examiner Name unknown

Sheet 2 of 4 Attorney Docket Number ANA-5955

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LW/		WERNER ET AL; Sevoflurane Improves Neurological Outcome After Incomplete Cerebral Ischaemia in Rats; Br J Anaesth.; Dec 1995; pp756-760; 75(6).	
		BEIRNE ET AL; Effect of Halothane in Cortical Cell Cultures Exposed to N-methyl-D-aspartate; Neurochem Res. Jan 1998; pp 17-23; 23(1).	
		GRADY ET AL; Correlation of Regional Cerebral Blood Flow with Ischemic Electroencephalographic Changes ...; Anesthesiology; April 1998; 88(4); pp 892-897.	
		SOONTHON-BRANT ET AL; Fentanyl Does Not Increase Brain Injury after Focal Ischemia in Rats; Anesth Analg.; January 1999; pp 49-55; 88(1).	
		PATEL ET AL; Isoflurane and Pentobarbital Reduce the Frequency of Transient Ischemic Depolarizations During Focal Ischemia in Rats; Anesth Analg.; Apr 1998; pp 773-80; 86(4).	
		MIURA ET AL; Differential Effects of Anesthetic Agents on Outcome from Near Complete but Not Incomplete Global Ischemia in the Rat; Anesthesiology Aug 1998; pp 289-291; 89(2).	
		DE HERT ET AL; Contraction-Relaxation Coupling and Impaired Left Ventricular Performance in Coronary Surgery Patients; Anesthesiology Mar 1999; pp 748-57; 90(3).	
		DE HERT ET AL; Length-Dependent Regulation of Left Ventricular Function in Coronary Surgery Patients; Anesthesiology Aug 1999; pp 379-87; 91(2).	
		DE HERT ET AL; The Effects of Beta-Adrenergic Stimulation on the Length-Dependent Regulation of Myocardial...; Anesth Analg. Oct 1999; pp 835-42; 89(4).	
/LW/		ENGELHARD ET AL; Desflurane and Isoflurane Improve Neurological Outcome after Incomplete Cerebral Ischaemia in Rats; Br J Anaesth. Sep 1999; pp 415-21; 83(3).	

Examiner Signature	/Leonard Williams/ (05/09/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/682,303

Filing Date October 9, 2000

First Named Inventor Trillo, Raul

Art Unit unknown

Examiner Name unknown

Sheet 3

of 4

Attorney Docket Number ANA-5955

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LW/		BELHOMME ET AL; Evidence for Preconditioning by Isoflurane in Coronary Artery Bypass Graft Surgery; Circulation Nov 9, 1999; pp 11-340-344.	
		WENKER OLIVER C; Review of Currently Used Inhalation Anesthetics : Part I; The Internet Journal of Anesthesiology 1999; vol 3(2).	
		WENKER OLIVER C; Review of Currently Used Inhalation Anesthetics : Part II; The Internet Journal of Anesthesiology 1999; vol 3(3).	
		KIMBRO ET AL; Isoflurane and Pentobarbital Reduce AMPA Toxicity In Vivo in the Rat Cerebral Cortex; Anesthesiology Mar 2000; pp 806-12; 92(3).	
		KAWAGUCHI ET AL; Isoflurane Delays but Does Not Prevent Cerebral Infarction In Rats Subjected to Focal Ischemia; Anesthesiology May 2000; pp 1335-42; 92(5).	
		ROSCOE ET AL; Isoflurane, but Not Halothane, Induces Protection of Human Myocardium via Adenosine A1 Receptors...; Anesthesiology Jun 2000; pp 1692-1701; 92(6).	
		TOLLER ET AL; Sarcolemmal and Mitochondrial Adenosine Triphosphate-Dependent Potassium Channels; Anesthesiology Jun 2000; pp 1731-1739; 92(6).	
		NELLGARD ET AL; Anesthetic Effects on Cerebral Metabolic Rate Predict Histological Outcome From...; Anesthesiology Aug 2000; pp 431-436; 93(2).	
		HANS ET AL; Neuroprotection with Anaesthetic Agents; Current Opinion in Anaesthesiology 2001; pp 491-496; vol. 14.	
/LW/		HAROUN-BIZRI ET AL; Does Isoflurane Optimize Myocardial Protection During Cardiopulmonary Bypass? J Cardiothorac Vasc Anesth. Aug 2001; pp 418-21; 15(4).	

Examiner
Signature

/Leonard Williams/ (05/09/2007)


Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/682,303

Filing Date October 9, 2000

First Named Inventor Trillo, Raul

Art Unit unknown

Examiner Name unknown

Sheet

4

of

4

Attorney Docket Number ANA-5955

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LW/		HANOUIZ ET AL; Mechanisms of Desflurane-Induced Preconditioning in Isolated Human Right Atria in Vitro; Anesthesiology Jul 2002; pp 33-41; 97(1).	
		DE HERT ET AL; Sevoflurane but Not Propofol Preserves Myocardial Function in Coronary Surgery Patients; Anesthesiology Jul 2002; pp 42-49; 97(1).	
		WARLTIER ET AL; Anesthetic Preconditioning; Serendipity and Science; Anesthesiology Jul 2002; pp 1-3; 97(1).	
		CUIGNET ET AL; A Second-Generation Blood Substitute (Perflubron Emulsion) Increases the Blood Solubility of Modern Volatile ...; Anesth Analg Aug 2002; pp 368-372.	
		PARK KW; Cardiovascular Effects of Inhalational Anesthetics; Int. Anesthesiol Clin; Winter 2002; pp 1-14; 40(1).	
		DE HERT ET AL; Effects of Propofol, Desflurane, and Sevoflurane on Recovery of Myocardial Function...; Anesthesiology Aug 2003; pp 314-23; 99(2).	
		CONZEN ET AL; Sevoflurane Provides Greater Protection of the Myocardium Than Propofol In Patients Undergoing Off-Pump...; Anesthesiology Oct 2003; pp 826-33; 99(4).	
/LW/		ENGELHARD ET AL; The Effect of Sevoflurane and Propofol On Cerebral Neurotransmitter Concentrations During Cerebral Ischemia in Rats; Anesth Analg. Oct 2003, pp 1155-61; 97(4)	

Examiner
Signature

/Leonard Williams/ (05/09/2007)

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.